Pay in 4 interest-free payments of $7.04 Learn more
Ships within 48 hours · Estimated delivery Aug 12 - Aug 17
It is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist
Cardiovascular safety trial demonstrating that the DPP-4 inhibitor sitagliptin does not increase MACE or hospitalization for heart failure in patients with T2DM and high cardiovascular risk
In 2013, diabetes affected 8.3% of the worldwide population
Safety Information Consult your healthcare professional before use if you are pregnant, nursing, taking medication, or have a medical condition
A healthcare professional can help you navigate your options, set realistic expectations, and ensure that any treatment you receive is appropriate, monitored, and as safe as possible
Moreover, some authors have suggested that hyperinsulinemia, hyperglycemia, and chronic inflammation typical of untreated DM would be risk factors for TC development and/or progression (Jee et al., 2005
US$ 22.32
US$ 20.17
US$ 28.61
US$ 21.48
US$ 21.99
US$ 25.19
